Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Therapy
Time to progression may be valuable surrogate marker in predicting breast cancer survival
January 26th, 2006
Time to progression may be a valuable surrogate marker in predicting survival in women receiving first-line anthracycline chemotherapy. "Surrogate markers may help predict the effects of first-line treatment on survival. This metaregression analysis examines the relationship between several surrogate markers and survival in women with advanced breast cancer after receiving first-line combination anthracycline chemotherapy 5-fluorouracil, adriamycin and cyclophosphamide (FAC) or 5-fluorouracil, epirubicin and cyclophosphamide (FEC)," researchers in England report. A. Hackshaw and colleagues wrote, "From a systematic literature review, we identified 42...
Source: Women's Health Weekly (2006-01-26)
|
